| OSA | osteosarcoma |
| NPs | nanoparticles |
| SLNs FDA |
solid lipid NPs Food and Drug Administration |
| AgNPs | silver NPs |
| AuNPs | gold NPs |
| DOXO | doxorubicin |
| CURC | curcumin |
| CNTs | carbon nanotubes |
| L-MTP-PE | liposome-encapsulated muramyl tripeptide phosphatidylethanolamine |
| PDGFRs | platelet derived growth factor receptors |
| MDR | multi-drug resistance |
| PTX | paclitaxel |
| CTI 52010 | formulation of nanoparticulate paclitaxel and normal saline |
| Pam | pamidronate |
| Au-GSH-DOXO | DOXO conjugated with glutathione-stabilized gold nanoparticles |
| P-gp | P-glycoprotein |
| CaP-NPs | calcium phosphate coated lipid NPs |
| SPI-77 | STEALH liposome-encapsulated cisplatin |
| ABC | accelerated blood clearance |
| NFP | peptide-based nanofiber precursor |
| NC-6300 | anticancer micelle of 60–70 nm |
| HIFU | high-intensity focused ultrasounds |
| OPLA-Pt | biodegradable polylactic acid-cisplatin containing implant |